Tadalafil and avanafil are both PDE5 inhibitors for erectile dysfunction, but their timing profiles emphasize different pharmacologic characteristics. Avanafil is rapidly absorbed and current STENDRA labeling permits 100 mg and 200 mg dosing as early as approximately 15 minutes before sexual activity, while tadalafil has a much longer terminal half-life and erectile-response evidence extending up to 36 hours after as-needed dosing.
Those statements describe different evidence layers. Avanafil's 15-minute wording is supported by a dedicated onset study and is not the same as its median fasting Tmax of approximately 30 to 45 minutes; tadalafil likewise has early-response evidence before its approximately 2-hour median Tmax.
This page compares onset context, peak timing, persistence, food effects, selectivity, dose frameworks, metabolism and safety without treating one metric as proof that either drug is universally better. Tadalafil-specific depth remains on dedicated pages such as tadalafil onset, half-life and duration.
The clearest contrast is earlier dose-to-sex timing on the avanafil side versus much longer persistence on the tadalafil side. Current STENDRA labeling allows its 100 mg starting dose to be taken as early as approximately 15 minutes before sexual activity, while current CIALIS labeling supports improved erectile function up to 36 hours after as-needed tadalafil.
Peak timing and half-life reinforce that difference without defining onset or duration by themselves. Avanafil reaches median peak concentration at approximately 30 to 45 minutes fasting and has a terminal half-life of about 5 hours; tadalafil reaches median peak concentration at about 2 hours and has a mean terminal half-life of 17.5 hours.
| Feature | Tadalafil | Avanafil |
|---|---|---|
| Drug class | PDE5 inhibitor | PDE5 inhibitor |
| ED brand | CIALIS | STENDRA |
| Median Tmax | About 2 h | About 30–45 min fasting |
| Terminal half-life | 17.5 h | About 5 h |
| Label timing | At least 30 min before anticipated sexual activity for PRN use | 100/200 mg: as early as ~15 min; 50 mg: ~30 min |
| Late response evidence | Improved erectile function demonstrated up to 36 h | No equivalent 36-hour-style claim |
| Food effect | No meaningful effect on rate or extent of absorption | High-fat meal delays Tmax and lowers Cmax |
| Once-daily labeled ED option | Yes | No |
| BPH indication | Yes | No |
| Sexual stimulation required | Yes | Yes |
Avanafil is absorbed more rapidly, while tadalafil persists much longer after absorption. Both are highly protein bound and depend substantially on CYP3A4 metabolism, but their circulating metabolites and overall concentration-time profiles differ.
The table deliberately separates administration timing from Tmax because those measurements answer different questions.
| Parameter | Tadalafil | Avanafil |
|---|---|---|
| Label ED timing | At least ~30 min before sexual activity for PRN use | 100/200 mg as early as ~15 min; 50 mg ~30 min |
| Median fasting Tmax | 2 h | 30–45 min |
| Observed Tmax range | 30 min–6 h | Median value is distinct from the 15-min label timing |
| Terminal half-life | 17.5 h | ~5 h |
| Protein binding | ~94% | ~99% |
| Primary metabolism | Predominantly CYP3A4 | Mainly CYP3A4; minor CYP2C contribution |
| Metabolite activity | Metabolites not expected to be pharmacologically active at observed concentrations | M4 contributes ~4% of total pharmacologic activity; M16 inactive against PDE5 |
| Major excretion pattern | ~61% feces, ~36% urine, predominantly as metabolites | ~62% feces, ~21% urine, predominantly as metabolites |
STENDRA 100 mg or 200 mg may be taken as early as approximately 15 minutes before sexual activity even though avanafil's median fasting Tmax is approximately 30 to 45 minutes. The label is not claiming that maximum plasma concentration occurs at 15 minutes.
CIALIS shows the same conceptual separation: counseling permits as-needed tadalafil from at least 30 minutes before anticipated sexual activity, while median Tmax is approximately 2 hours. Clinical timing reflects observed response under studied conditions; Tmax reflects peak plasma concentration.
| Timing measure | Tadalafil | Avanafil |
|---|---|---|
| Earliest relevant label timing | At least ~30 min | As early as ~15 min at 100/200 mg |
| Median Tmax | ~2 h | ~30–45 min |
| Timing equals Tmax? | No | No |
Current STENDRA labeling describes a randomized, double-blind, placebo-controlled onset study involving 440 subjects with ED. Participants attempted intercourse approximately 15 minutes after dosing; the mean proportion of attempts resulting in an erection sufficient for penetration followed by successful intercourse was 14.9% with placebo, 25.9% with avanafil 100 mg and 29.1% with avanafil 200 mg.
Current CIALIS labeling describes a separate stopwatch study evaluating successful erections at or before 30 minutes. Results were 35% with placebo, 38% with tadalafil 10 mg and 52% with tadalafil 20 mg, using a study definition based on at least one erection in four attempts leading to successful intercourse.
These studies support early-response claims for each drug, but their percentages cannot be compared as if the participants had been randomized directly between tadalafil and avanafil.
| Early-response evidence | Placebo | Lower active dose | Higher active dose |
|---|---|---|---|
| Avanafil at ~15 min | 14.9% | 25.9% at 100 mg | 29.1% at 200 mg |
| Tadalafil at or before 30 min | 35% | 38% at 10 mg | 52% at 20 mg |
| Direct head-to-head comparison? | No | No | No |
The avanafil and tadalafil studies used different patient samples, doses, timing windows and endpoint structures. Comparing 29.1% from the avanafil study with 52% from the tadalafil study would therefore create false head-to-head evidence.
The defensible conclusion is narrower: avanafil has direct approximately-15-minute evidence at 100 mg and 200 mg, while tadalafil has separate evidence at or before 30 minutes plus a much broader late-response evidence base.
| Comparison | Supported? |
|---|---|
| Avanafil has placebo-controlled ~15-min evidence | Yes |
| Tadalafil has separate ≤30-min evidence | Yes |
| Raw percentages prove direct superiority | No |
| Label timing can be compared directly | Yes |
Tadalafil has a mean terminal half-life of approximately 17.5 hours, compared with about 5 hours for avanafil. That difference creates a substantially longer tadalafil concentration-time tail and is consistent with a broader post-dose treatment profile.
The clinical duration evidence is asymmetrical. Current CIALIS labeling contains dedicated data showing improved erectile function up to 36 hours after dosing, including controlled late-timepoint assessments, whereas current STENDRA labeling does not provide a directly comparable tadalafil-style late-hour claim.
The longer tadalafil half-life helps explain persistence but does not by itself establish the 36-hour clinical window. Half-life and clinical duration remain separate concepts, as explained in more depth on the tadalafil half-life page and 36-hour evidence page.
| Persistence concept | Tadalafil | Avanafil |
|---|---|---|
| Terminal half-life | 17.5 h | ~5 h |
| Concentration-time tail | Much longer | Shorter |
| Explicit late-response claim | Up to 36 h | No directly comparable late-hour claim |
| Half-life equals exact clinical duration | No | No |
| Continuous erection implied | No | No |
Tadalafil's rate and extent of absorption are not meaningfully influenced by food, so current CIALIS labeling permits dosing without regard to meals. STENDRA can also be taken with or without food, but a high-fat meal changes avanafil's absorption profile.
With avanafil 200 mg, current labeling reports a mean Tmax delay of approximately 1.12 to 1.25 hours, a 39% reduction in Cmax and only about a 3.8% reduction in AUC. The label considers the overall exposure change of minimal clinical significance, although the delayed peak remains relevant to timing comparisons.
Tadalafil's meal-specific PK is covered on the tadalafil food-effects page.
| High-fat meal effect | Tadalafil | Avanafil 200 mg |
|---|---|---|
| May be taken with or without food | Yes | Yes |
| Tmax change | No meaningful label-described effect | Delayed ~1.12–1.25 h |
| Cmax change | No meaningful effect | Reduced ~39% |
| AUC change | No meaningful effect | Reduced ~3.8% |
Current CIALIS labeling starts most as-needed ED patients at 10 mg, with 5 mg and 20 mg adjustment options. STENDRA starts at 100 mg, with 50 mg and 200 mg alternatives, but those larger numerical doses do not mean avanafil is five or ten times weaker than tadalafil.
STENDRA timing is also dose specific: 100 mg and 200 mg may be taken as early as approximately 15 minutes before sexual activity, while 50 mg is labeled for approximately 30 minutes beforehand. Milligram values describe different molecules and do not create a cross-drug potency conversion.
Tadalafil's own regimen structure belongs on the tadalafil dosage page.
| ED framework | Tadalafil / CIALIS | Avanafil / STENDRA |
|---|---|---|
| Typical starting dose | 10 mg | 100 mg |
| Lower option | 5 mg | 50 mg |
| Higher option | 20 mg | 200 mg |
| Timing at lower option | PRN CIALIS framework | ~30 min at 50 mg |
| Timing at starting / upper option | At least ~30 min in CIALIS counseling | As early as ~15 min at 100/200 mg |
| Direct mg-to-mg equivalence | No | No |
CIALIS labeling includes both as-needed and once-daily ED treatment, while STENDRA remains an as-needed ED drug. The tadalafil daily framework uses lower doses taken at approximately the same time each day without regard to sexual timing.
CIALIS also carries indications for BPH and combined ED/BPH, and tadalafil appears in separate pulmonary arterial hypertension products. STENDRA is an ED-specific product and does not have comparable BPH or PAH labeling.
These additional tadalafil uses do not prove greater ED efficacy. They represent different approved clinical contexts, covered in more detail on the BPH page and PAH page.
| Label context | Tadalafil | Avanafil |
|---|---|---|
| As-needed ED | Yes | Yes |
| Once-daily ED | Yes | No |
| BPH | Yes | No |
| Combined ED + BPH | Yes | No |
| Separate PAH product context | Yes | No |
Current STENDRA labeling reports avanafil as more than 100-fold more potent for PDE5 than PDE6 and more than 10,000-fold more potent for PDE5 than PDE1, PDE3, PDE9 and PDE11. Current CIALIS labeling reports tadalafil as approximately 700-fold more potent for PDE5 than PDE6, while its selectivity over PDE11A1 and PDE11A4 is smaller.
Those laboratory ratios should not be converted into an overall clinical-safety ranking. Current tadalafil labeling states that the physiological role and clinical consequences of PDE11 inhibition in humans remain undefined, so it would be too strong to claim that avanafil's PDE11 selectivity proves better muscular tolerability or that tadalafil back pain is definitively caused by PDE11 inhibition.
| In-vitro selectivity | Tadalafil | Avanafil |
|---|---|---|
| PDE5 vs PDE6 | ~700-fold | >100-fold |
| PDE5 vs PDE3 | >10,000-fold | >10,000-fold |
| PDE5 vs PDE11 | 14-fold vs PDE11A1; 40-fold vs PDE11A4 | >10,000-fold |
| Proves overall clinical superiority? | No | No |
| PDE11 proven cause of tadalafil back pain? | No | Not applicable |
Tadalafil is predominantly metabolized by CYP3A4, and its metabolites are not expected to be pharmacologically active at observed concentrations. Avanafil is also cleared mainly through CYP3A4, with a minor CYP2C contribution; its M4 metabolite reaches about 23% of parent plasma concentration, has about 18% of parent PDE5 inhibitory potency and contributes approximately 4% of total pharmacologic activity, while M16 is inactive against PDE5.
Shared CYP3A4 dependence does not mean identical interaction instructions. Current STENDRA labeling says not to use avanafil with strong CYP3A4 inhibitors and limits use with moderate CYP3A4 inhibitors to a maximum of 50 mg in 24 hours, while CIALIS uses its own dose-and-frequency restriction framework.
Tadalafil-specific CYP3A evidence belongs on the tadalafil CYP3A4 page.
| CYP3A feature | Tadalafil | Avanafil |
|---|---|---|
| Major pathway | CYP3A4 | CYP3A4 |
| Additional route | No comparable minor route emphasized | Minor CYP2C contribution |
| Strong CYP3A inhibitor framework | Tadalafil-specific dose/frequency limits | Do not use |
| Moderate CYP3A inhibitor framework | Product-specific tadalafil instructions | Maximum 50 mg in 24 h |
| Can interaction rules be transferred between drugs? | No | No |
Both drugs are contraindicated with organic nitrates and guanylate cyclase stimulators because PDE5 inhibition can potentiate hypotension. Current CIALIS labeling uses an emergency minimum of at least 48 hours after tadalafil before nitrate consideration in a life-threatening situation, whereas STENDRA uses at least 12 hours after avanafil; both still require close medical supervision and hemodynamic monitoring.
Both labels also require caution with alpha-blockers and other blood-pressure-lowering exposures. Patients should be stable on alpha-blocker therapy before PDE5 inhibition is introduced; STENDRA uses a 50 mg initiation framework in that context, while tadalafil has its own ED-specific and BPH-specific alpha-blocker rules.
Substantial alcohol can also increase orthostatic and blood-pressure effects with either drug. These shared class effects remain important even though avanafil has high in-vitro PDE5 selectivity.
| Interaction context | Tadalafil | Avanafil |
|---|---|---|
| Organic nitrates | Contraindicated | Contraindicated |
| Emergency nitrate minimum | At least 48 h | At least 12 h |
| GC stimulators | Contraindicated | Contraindicated |
| Alpha-blocker stability relevant | Yes | Yes |
| Alpha-blocker initiation detail | Tadalafil-specific ED/BPH framework | Start STENDRA at 50 mg |
| Substantial alcohol can increase orthostatic risk | Yes | Yes |
| Routine self-directed nitrate interval | No | No |
Both tadalafil and avanafil can cause headache, flushing, nasal symptoms and other effects related to PDE5 inhibition and vasodilation. STENDRA labeling lists headache, flushing, nasal congestion, nasopharyngitis and back pain among its most common adverse reactions, while tadalafil labeling also prominently includes dyspepsia, back pain and myalgia.
Both labels also address cardiovascular suitability for sexual activity, prolonged erections or priapism, sudden vision changes including NAION reports and sudden hearing decrease or loss. Raw adverse-event percentages from their separate development programs should not be compared as if they came from one randomized head-to-head trial.
Tadalafil's detailed adverse-reaction and warning profiles remain on the side-effects page and warnings page.
| Safety category | Tadalafil | Avanafil |
|---|---|---|
| Headache | Common | Common |
| Flushing / nasal symptoms | Reported | Common |
| Back pain | Prominent common reaction | Also reported |
| Erection >4 h | Emergency warning | Emergency warning |
| Sudden vision / hearing warnings | Yes | Yes |
| Cross-trial percentage ranking valid? | No | No |
Both tadalafil and avanafil demonstrated erectile-dysfunction efficacy against placebo in their own development programs. That supports effectiveness of each treatment within the conditions in which it was studied.
It does not justify comparing unrelated response percentages as if they came from a direct tadalafil-versus-avanafil trial. The most defensible pairwise comparison therefore centers on label timing, pharmacokinetics, food effects, regimen options and safety rather than on a manufactured superiority claim.
| Comparison approach | Supported? |
|---|---|
| Both demonstrated efficacy vs placebo | Yes |
| Separate trial percentages prove direct superiority | No |
| Compare Tmax, half-life and food effects directly | Yes |
| Compare label timing directly | Yes |
| Declare a universal winner | No |
Current labeling does not establish one drug as universally better. Avanafil offers earlier dose-to-sex timing, including approximately-15-minute use at 100 mg and 200 mg, while tadalafil provides much longer persistence, an up-to-36-hour as-needed response window and a once-daily ED option.
Food pharmacology, CYP3A interactions and indications also differ. Tadalafil absorption is unaffected by food and CIALIS has BPH indications, while avanafil is an ED-specific product whose high-fat meal effect primarily changes peak timing and concentration.
The useful comparison is therefore earlier timing versus broader persistence and regimen flexibility, not a single best-drug verdict.
| Comparison priority | Tadalafil | Avanafil |
|---|---|---|
| Earlier label timing | At least ~30 min | As early as ~15 min at 100/200 mg |
| Earlier median peak | ~2 h | ~30–45 min |
| Longer persistence | 17.5 h half-life | ~5 h half-life |
| Broad late-response evidence | Up to 36 h | No equivalent label claim |
| Food-independent absorption | Yes | No |
| Once-daily ED option | Yes | No |
| Universal winner | No | No |
Avanafil's 15-minute label timing does not mean every patient responds exactly at 15 minutes or that plasma concentration has already peaked. Tadalafil's approximately 2-hour Tmax likewise does not mean the drug cannot support an erectile response earlier.
The drugs' milligram values are not potency equivalents, their half-lives are not exact efficacy clocks and tadalafil's 36-hour window does not mean a continuous erection. High in-vitro PDE5 selectivity also does not remove clinically important nitrate, alpha-blocker or blood-pressure interactions.
| Misunderstanding | Correct interpretation |
|---|---|
| Avanafil peaks at 15 min | No; median fasting Tmax is ~30–45 min |
| Every patient responds to avanafil at 15 min | No |
| Tadalafil cannot respond before its 2-h Tmax | Incorrect |
| Tadalafil creates a continuous erection for 36 h | No |
| Avanafil works exactly 5 h because half-life is ~5 h | No |
| 100 mg avanafil is five times stronger than 20 mg tadalafil | No |
| Higher PDE5 selectivity removes major interactions | No |
The most useful comparison asks whether the key difference is early dose-to-sex timing, long post-dose flexibility, meal sensitivity, daily treatment or a specific interaction profile. Those characteristics can be compared directly without converting separate clinical trials into an artificial ranking.
Keeping label timing, clinical-response evidence and PK measurements separate is particularly important for this pair.
| Question | Why it matters |
|---|---|
| Is early timing the priority? | Avanafil has explicit ~15-min timing at 100/200 mg |
| Is a broad post-dose window relevant? | Tadalafil has up-to-36-h response evidence |
| Is Tmax being confused with onset? | The concepts differ for both drugs |
| Does food timing matter? | Tadalafil is food independent; high-fat meals alter avanafil absorption rate |
| Is once-daily ED treatment relevant? | Available for tadalafil, not STENDRA |
| Is BPH part of the context? | CIALIS has BPH indications; STENDRA does not |
| Are CYP3A inhibitors present? | The labels use different management rules |
| Are nitrates or GC stimulators present? | Both combinations are contraindicated |
Tadalafil and avanafil share the PDE5 mechanism but have markedly different timing profiles. Avanafil has a median fasting Tmax of approximately 30 to 45 minutes, an approximately 5-hour terminal half-life and label-supported 100/200 mg administration as early as about 15 minutes before sexual activity; tadalafil has a median Tmax of about 2 hours and a much longer 17.5-hour terminal half-life.
Clinical timing remains separate from PK peak timing. Avanafil has a dedicated placebo-controlled approximately-15-minute onset study, while tadalafil has separate early-response evidence at or before 30 minutes plus clinical evidence extending up to 36 hours.
Neither profile creates a universal winner. Avanafil emphasizes earlier as-needed timing, while tadalafil offers broader persistence, food-independent absorption, a once-daily ED framework and additional indication contexts.
Avanafil emphasizes earlier dose-to-sex timing, while tadalafil has much longer pharmacokinetic persistence. Avanafil can be taken as early as approximately 15 minutes before sexual activity at 100 mg or 200 mg, while tadalafil has a 17.5-hour half-life and response evidence extending up to 36 hours.
Yes. STENDRA contains avanafil as its active ingredient.
Avanafil reaches median peak plasma concentration at approximately 30 to 45 minutes fasting, compared with approximately 2 hours for tadalafil.
Current STENDRA labeling permits 100 mg and 200 mg dosing as early as approximately 15 minutes before sexual activity, and a placebo-controlled study demonstrated statistically significant successful-intercourse outcomes around that time. This does not mean every patient responds at 15 minutes.
No. Its median fasting Tmax is approximately 30 to 45 minutes. Label timing and peak plasma concentration are different measurements.
Current CIALIS labeling supports as-needed sexual activity from about 30 minutes after dosing, and a separate controlled study evaluated successful erections at or before 30 minutes.
Tadalafil has the substantially longer pharmacokinetic profile, with a mean terminal half-life of 17.5 hours compared with approximately 5 hours for avanafil. CIALIS also has clinical response evidence extending up to 36 hours.
Current STENDRA labeling reports an approximately 5-hour terminal half-life but does not provide a tadalafil-style universal late-response claim. Half-life should not be treated as an exact duration of erectile effect.
Both may be taken with or without food. Food does not meaningfully affect tadalafil absorption, while a high-fat meal delays avanafil Tmax and lowers Cmax with only a small change in AUC.
With avanafil 200 mg, current labeling reports a mean Tmax delay of approximately 1.12 to 1.25 hours, a Cmax reduction of about 39% and an AUC decrease of about 3.8%.
No. Current STENDRA labeling uses an as-needed ED framework, while CIALIS also has a once-daily ED option.
No. They are different molecules with different dose ranges and pharmacokinetic properties, so their milligram values cannot be converted directly.
Both are highly selective PDE5 inhibitors with different in-vitro selectivity profiles. Those laboratory ratios do not establish overall clinical superiority or prove that one drug has fewer adverse effects.
Yes. CYP3A4 is the predominant pathway for both, although current avanafil labeling also describes a minor CYP2C contribution.
Current STENDRA labeling states not to use avanafil with strong CYP3A4 inhibitors. Tadalafil uses a different product-specific dose and frequency restriction framework.
Yes. Organic nitrates are contraindicated with both because PDE5 inhibition can potentiate severe blood-pressure lowering.
Current CIALIS labeling uses at least 48 hours after tadalafil, while STENDRA uses at least 12 hours after avanafil when nitrate administration is medically necessary in a life-threatening situation. Both still require close medical supervision and are not routine self-directed waiting rules.
Yes. Current labeling contraindicates both with guanylate cyclase stimulators because of the risk of excessive hypotension.
Current PDE5-inhibitor labeling does not establish the safety or efficacy of combining these ED therapies, so they should not be treated as stackable doses.
Current labeling does not establish a universal winner. Avanafil emphasizes earlier as-needed timing, while tadalafil offers much longer persistence, an up-to-36-hour response window, food-independent absorption and a once-daily ED option.